Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: June 23, 2009
Event: Entry into a Material Definitive Agreement (Underwriting Agreement) for a public offering of common stock.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt levels. It details a specific capital raising transaction:
- Shares to be Sold: 6,150,000 shares of common stock.
- Offering Price: $6.50 per share.
- Gross Proceeds (Estimated): $40,000,000 (6,150,000 shares x $6.50).
- Underwriter: Jefferies & Company, Inc.
- Expected Closing Date: June 26, 2009.
Material Changes
The filing announces a material change in the company's capital structure through the execution of an Underwriting Agreement. This represents a planned increase in equity capital. The filing references a shelf registration statement (Form S-3, File No. 333-155787) declared effective on January 8, 2009, which facilitates this offering.
Guidance, Outlook, and Risks
Management Commentary: The company expects the transaction to close on June 26, 2009, subject to customary conditions.
Risks and Contingencies:
- The closing of the offering is not guaranteed and depends on the satisfaction of certain conditions.
- Forward-looking statements regarding the anticipated closing and net proceeds involve risks and uncertainties.
- Additional risks are detailed in the Company's Form 10-K for the year ended December 31, 2008.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 26, 2009).
- Confirm the actual net proceeds after deducting underwriting discounts and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific conditions precedent to closing.
- Check subsequent filings for any updates on the status of the offering or changes in the number of shares sold.